How New Approach Methodologies work together to revolutionize drug development and eliminate the need for animal testing
Human Biology Platform
3D tissue models
Microfluidic systems
Virtual patients
Pattern discovery
Computer models
New Approach Methodologies (NAMs) aren't isolated technologies - they form an integrated ecosystem where each component enhances the others. Organoids provide biological tissue for testing, organ-on-chips add physiological flow and mechanical forces, digital twins personalize predictions to individual patients, AI accelerates discovery and pattern recognition, and in silico models enable rapid computational screening.
Together, these technologies create a complete human biology platform that can predict drug effects more accurately than animal testing while being faster, cheaper, and more ethical.
Mini-organs grown from stem cells that self-organize into 3D structures mimicking real organ architecture. Used for disease modeling and personalized drug testing.
Microfluidic devices with living cells that recreate organ physiology including blood flow, breathing motions, and multi-organ interactions.
Virtual patient models integrating genomics, medical history, and physiology to simulate individual drug responses before treatment.
Artificial intelligence systems that analyze massive datasets to discover drug candidates, predict toxicity, and optimize clinical trials.
Computational simulations of biological processes, from molecular docking to whole-body pharmacokinetics, enabling virtual experiments.
Screen millions of compounds
Optimize top candidates
Test on human tissue
Multi-organ effects
Virtual patient testing
Try our interactive simulations to see these technologies in action
Explore Simulations Start Learning Path